1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials
Takashi Muramatsu, Yoshinobu Onuma, Robert-Jan van Geuns, Bernard Chevalier, Tejas M Patel, Ashok Seth, Roberto Diletti, Hector M García-García, Cécile C Dorange, Susan Veldhof, Wai-Fung Cheong, Yukio Ozaki, Robert Whitbourn, Antonio Bartorelli, Gregg W Stone, Alexandre Abizaid, Patrick W Serruys, ABSORB Cohort B Investigators, ABSORB EXTEND Investigators, SPIRIT FIRST Investigators, SPIRIT II Investigators, SPIRIT III Investigators, SPIRIT IV Investigators, Takashi Muramatsu, Yoshinobu Onuma, Robert-Jan van Geuns, Bernard Chevalier, Tejas M Patel, Ashok Seth, Roberto Diletti, Hector M García-García, Cécile C Dorange, Susan Veldhof, Wai-Fung Cheong, Yukio Ozaki, Robert Whitbourn, Antonio Bartorelli, Gregg W Stone, Alexandre Abizaid, Patrick W Serruys, ABSORB Cohort B Investigators, ABSORB EXTEND Investigators, SPIRIT FIRST Investigators, SPIRIT II Investigators, SPIRIT III Investigators, SPIRIT IV Investigators
Abstract
Objectives: The aim of this study was to evaluate 1-year clinical outcomes of diabetic patients treated with the Absorb bioresorbable vascular scaffold (BVS).
Background: Clinical outcomes of diabetic patients after BVS implantation have been unreported.
Methods: This study included 101 patients in the ABSORB Cohort B trial and the first consecutive 450 patients with 1 year of follow-up in the ABSORB EXTEND trial. A total of 136 diabetic patients were compared with 415 nondiabetic patients. In addition, 882 diabetic patients treated with everolimus-eluting metal stents (EES) in pooled data from the SPIRIT trials (SPIRIT FIRST [Clinical Trial of the Abbott Vascular XIENCE V Everolimus Eluting Coronary Stent System], SPIRIT II [A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System], SPIRIT III [Clinical Trial of the XIENCE V Everolimus Eluting Coronary Stent System (EECSS)], SPIRIT IV Clinical Trial [Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System]) were used for the comparison by applying propensity score matching. The primary endpoint was a device-oriented composite endpoint (DoCE), including cardiac death, target vessel myocardial infarction, and target lesion revascularization at 1-year follow-up.
Results: The cumulative incidence of DoCE did not differ between diabetic and nondiabetic patients treated with the BVS (3.7% vs. 5.1%, p = 0.64). Diabetic patients treated with the BVS had a similar incidence of the DoCE compared with diabetic patients treated with EES in the matched study group (3.9% for the BVS vs. 6.4% for EES, p = 0.38). There were no differences in the incidence of definite or probable scaffold/stent thrombosis (0.7% for both diabetic and nondiabetic patients with the BVS; 1.0% for diabetic patients with the BVS vs. 1.7% for diabetic patients with EES in the matched study group).
Conclusions: In the present analyses, diabetic patients treated with the BVS showed similar rates of DoCEs compared with nondiabetic patients treated with the BVS and diabetic patients treated with EES at 1-year follow-up. (ABSORB Clinical Investigation, Cohort B; NCT00856856; ABSORB EXTEND Clinical Investigation; NCT01023789; Clinical Trial of the Abbott Vascular XIENCE V Everolimus Eluting Coronary Stent System [SPIRIT FIRST]; NCT00180453; A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System [SPIRIT II]; NCT00180310; Clinical Trial of the XIENCE V Everolimus Eluting Coronary Stent System [EECSS] [SPIRIT III]; NCT00180479; Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System [SPIRIT IV Clinical Trial]; NCT00307047).
Keywords: bioresorbable scaffold; coronary artery disease; diabetes mellitus; drug-eluting stent.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Source: PubMed